Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Intangibles (2022 - 2025)

Neurocrine Biosciences' Intangibles history spans 4 years, with the latest figure at $35.7 million for Q3 2025.

  • For Q3 2025, Intangibles rose 3.48% year-over-year to $35.7 million; the TTM value through Sep 2025 reached $35.7 million, up 3.48%, while the annual FY2024 figure was $36.5 million, 2.82% up from the prior year.
  • Intangibles reached $35.7 million in Q3 2025 per NBIX's latest filing, down from $37.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $37.2 million in Q4 2022 to a low of $33.5 million in Q2 2024.
  • Average Intangibles over 4 years is $35.8 million, with a median of $36.0 million recorded in 2025.
  • Peak YoY movement for Intangibles: decreased 9.21% in 2024, then increased 11.04% in 2025.
  • A 4-year view of Intangibles shows it stood at $37.2 million in 2022, then fell by 4.57% to $35.5 million in 2023, then rose by 2.82% to $36.5 million in 2024, then fell by 2.19% to $35.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Intangibles are $35.7 million (Q3 2025), $37.2 million (Q2 2025), and $36.4 million (Q1 2025).